Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

Table 3 Effectiveness of 12-week adalimumab treatment in patients with AS stratified by prior anti-TNF therapy

Outcome measure	No prior ETN/IFX	Prior ETN and/or IFX
	(n = 924)	(n = 326)
BASDAI (0 to 10)
Baseline	6.2	6.5
	5.2, 7.2	5.5, 7.6
Change, Baseline to week 12	-3.7	-2.5
	-5.1, -1.9	-4.2, -1.0
BASFI (0 to 10)
Baseline	5.2	6.0
	3.5, 7.0	4.3, 7.5
Change, Baseline to week 12	-2.2	-1.3
	-3.9, -0.8	-2.8, -0.1
Patients with peripheral arthritis (SJC ≥ 1)	n = 201	n = 80
TJC (0 to 46)
Baseline	4	6
	2, 11	3, 14
Change, Baseline to week 12	-3	-3
	-8, -1	-8, -1
SJC (0 to 44)
Baseline	2	2
	1, 4	1, 4
Change, Baseline to week 12	-2	-1
	-4, -1	-2, -1
Patients with enthesitis (MASES ≥ 1)	n = 492	n = 175
MASES (0 to 13)
Baseline	5	5
	2, 8	3, 9
Change, Baseline to week 12	-3	-2
	-5, -1	-5 , -1

Values are expressed as median and quartile 1, quartile 3. AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; ETN, etanercept; IFX, infliximab; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; TJC, tender joint count; TNF, tumor necrosis factor; SJC, swollen joint count.

ISSN: 1478-6362